{
    "clinical_study": {
        "@rank": "16754", 
        "arm_group": [
            {
                "arm_group_label": "Ragweed-SPIRE 1", 
                "arm_group_type": "Experimental", 
                "description": "Ragweed SPIRE regimen 1 given 2 weeks apart"
            }, 
            {
                "arm_group_label": "Ragweed-SPIRE 2", 
                "arm_group_type": "Experimental", 
                "description": "Ragweed-SPIRE regimen 2 given 2 weeks apart"
            }, 
            {
                "arm_group_label": "Ragweed-SPIRE 3", 
                "arm_group_type": "Experimental", 
                "description": "Ragweed-SPIRE regimen 3 given 2 weeks apart"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given 2 weeks apart"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at\n      reducing allergy symptoms in people who suffer from allergy to Ragweed pollen"
        }, 
        "brief_title": "Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 18-65 years.\n\n          -  Reliable history consistent with moderate to severe rhinoconjunctivitis on exposure\n             to ragweed for at least the previous two seasons.\n\n          -  Minimum qualifying rhinoconjunctivitis symptom scores\n\n          -  Ragweed-specific Immunoglobulin E (IgE) > 0.70 kU/L.\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of ragweed pollen induced asthma\n\n          -  A history of anaphylaxis to ragweed allergen.\n\n          -  FEV1 < 80 % of predicted.\n\n          -  Subjects who cannot tolerate Baseline Challenge in the EEC.\n\n          -  Subjects for whom administration of epinephrine is contraindicated (e.g. subjects\n             with acute or chronic symptomatic coronary heart disease or severe hypertension).\n\n          -  History of immunopathological diseases (e.g. multiple sclerosis) that in the opinion\n             of the Investigator or the Sponsor could interfere with the results obtained from the\n             study.\n\n          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.\n\n          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,\n             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,\n             neoplastic/malignant, psychiatric, major physical impairment)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061709", 
            "org_study_id": "TR006"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ragweed-SPIRE 1", 
                    "Ragweed-SPIRE 2", 
                    "Ragweed-SPIRE 3"
                ], 
                "intervention_name": "Ragweed-SPIRE", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rhinoconjunctivitis", 
            "Rhinitis", 
            "Seasonal", 
            "Ragweed", 
            "Allergy"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kanata", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K2L 3C8"
                    }, 
                    "name": "Kanata Allergy Services"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5R8"
                    }, 
                    "name": "KGK Synergize Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mississauga", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8P 0A1"
                    }, 
                    "name": "Inflamax Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oshawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L1H 7K4"
                    }, 
                    "name": "Taunton Health Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Windsor", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N8X 2G1"
                    }, 
                    "name": "Windsor Allergy Asthma Associates"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber", 
        "overall_official": {
            "affiliation": "Inflamax Research", 
            "last_name": "Piyush Patel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in mean Total Rhinoconjunctivitis Symptom Score (TRSS)", 
            "safety_issue": "No", 
            "time_frame": "Between Baseline and approximately 25 weeks after randomisation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in mean Total Rhinoconjunctivitis Symptom Score (TRSS) - all timepoints", 
                "safety_issue": "No", 
                "time_frame": "Between Baseline and approximately 25 weeks after randomisation"
            }, 
            {
                "measure": "Change from Baseline in mean Total Nasal Symptom Score (TNSS)", 
                "safety_issue": "No", 
                "time_frame": "Aproximately 25 weeks after randomisation"
            }, 
            {
                "measure": "Change from Baseline in mean Total Non Nasal Symptom Scores (TNNSS)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 25 weeks after randomisation"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 28 weeks"
            }
        ], 
        "source": "Circassia Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Adiga Life Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Circassia Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}